Abstract
Re: Shah et al.: Teprotumumab-related adverse events in thyroid eye disease: a multicenter study (Ophthalmology. 2023 Oct 16:S0161-6420(23)00760-1)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
